AZD1152 in Patients With Advanced Solid Malignancies-Study 3

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00497679

Enrollment

Registered

2007-07-09

Start date

2006-08-31

Completion date

2007-07-31

Last updated

2009-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumours

Keywords

advanced solid tumours

Brief summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.

Interventions

DRUGAZD1152

7-day continuous intravenous infusion

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological or cytological confirmation of a solid, malignant tumour

Exclusion criteria

* Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug * Treatment with radiotherapy/chemotherapy with 4 weeks of first dose * Recent major surgery within 4 weeks prior to entry to the study

Design outcomes

Primary

Measure	Time frame
Safety and Tolerability	Assessed at each visit

Secondary

Measure	Time frame
Pharmacokinetics	Assessed at predetermined timepoints after dose administration
Effect on biomarkers	Assessed after treatment
Anti-tumor activity	Assessed at the end of treatment

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026